Loading...
Market
Will Datopotamab Deruxtecan sales exceed $1 billion in 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Annual financial reports of AstraZeneca and Daiichi Sankyo
Story
FDA Approves Datopotamab Deruxtecan With Improved PFS for Advanced HR+/HER2- Breast Cancer
Jan 17, 2025, 12:23 PM
The FDA has approved datopotamab deruxtecan (Datroway) for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer in adults who have previously received endocrine-based therapy and chemotherapy. The approval is supported by the TROPION-Breast01 trial, which showed a median progression-free survival of 6.9 months for Datroway compared to 4.9 months for chemotherapy (HR, 0.63). The trial also reported a median overall survival of 18.6 months for Datroway versus 18.3 months for chemotherapy. Common adverse effects included stomatitis, nausea, and fatigue. Datopotamab deruxtecan is co-developed by AstraZeneca and Daiichi Sankyo, marking a significant advancement in targeted cancer therapies.
View original story
Similar markets
$500 million to $1 billion • 25%
Less than $500 million • 25%
More than $2 billion • 25%
$1 billion to $2 billion • 25%
Increase by more than 20% • 25%
Increase between 10% and 20% • 25%
No significant increase • 25%
Increase by less than 10% • 25%
Significant survival improvement • 25%
Trial stopped early for safety concerns • 25%
Trial stopped early for efficacy • 25%
No significant survival improvement • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
